
Opinion|Videos|August 14, 2024
Comparing Telomerase Inhibitors and EMAs in ESA-Ineligible LR MDS
Author(s)Abdulraheem Yacoub, MD
Advertisement
Episodes in this series

- Please share your thoughts about the choice between an EMA versus a telomerase inhibitor in the LR-MDS ESA ineligible patient?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















